New data provide schizophrenia treatment insights into switching to uzedy® (risperidone) extended-release injectable suspension from invega sustenna® (paliperidone palmitate)

Tel aviv, israel & parsippany, n.j.--(business wire)--teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today announced the presentation of seven studies from its long-acting injectable (lai) schizophrenia research program. presentations include data informing clinical strategies for switching patients to uzedy, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophren.
TEVA Ratings Summary
TEVA Quant Ranking